Yahoo Finance·2025-12-28 15:58Core Insights - Salesforce, Inc. (NYSE:CRM) is recognized as one of the best quality stocks to buy before 2026, particularly following its announcement of a partnership with Novartis to enhance customer engagement in the healthcare sector [1] Group 1: Partnership and Investment - Novartis has previously invested in Salesforce through various platforms including Agentforce Health and MuleSoft for Life Sciences, and now aims to unify engagement across multiple teams over the next five years [2] - The partnership will involve the global deployment of Agentforce 360 for Life Sciences, indicating a significant commitment to integrating Salesforce's technology within Novartis [2] Group 2: Market Sentiment and Analyst Ratings - Wall Street analysts are optimistic about Salesforce, with BTIG's Allan Verkhovski initiating coverage with a Buy rating and a price target of $335, while Mizuho Securities' Gregg Moskowitz reiterated a Buy rating with a $340 price target [3] - Analyst Verkhovski appreciates Salesforce's re-architecture of its core platform and anticipates that the company's net new annual order value will accelerate, leading to a return to double-digit subscription revenue growth by fiscal Q4 2027 [4]